iRhythm TechnologiesIRTC
Market Cap: $2.1B
About: iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company's portfolio includes ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for several days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.
Employees: 2,000
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
63% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 64
3.01% more ownership
Funds ownership: 111.15% [Q1] → 114.16% (+3.01%) [Q2]
4% less capital invested
Capital invested by funds: $3.99B [Q1] → $3.82B (-$171M) [Q2]
10% less funds holding
Funds holding: 249 [Q1] → 225 (-24) [Q2]
46% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 52
48% less call options, than puts
Call options by funds: $17.2M | Put options by funds: $32.8M
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
Citigroup Joanne Wuensch 66% 1-year accuracy 25 / 38 met price target | 64%upside $110 | Buy Maintained | 22 Aug 2024 |
JP Morgan Allen Gong 56% 1-year accuracy 5 / 9 met price target | 49%upside $100 | Overweight Maintained | 2 Aug 2024 |
Oppenheimer Suraj Kalia 53% 1-year accuracy 9 / 17 met price target | 116%upside $145 | Outperform Maintained | 2 Aug 2024 |
Baird Mike Polark 57% 1-year accuracy 4 / 7 met price target | 64%upside $110 | Outperform Maintained | 2 Aug 2024 |
Truist Securities Richard Newitter 67% 1-year accuracy 29 / 43 met price target | 74%upside $117 | Buy Reiterated | 2 Aug 2024 |
Financial journalist opinion
Based on 7 articles about IRTC published over the past 30 days